Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

C4X banks $13m as AstraZeneca doses

1 min read
18:53UTC

C4X Discovery earned a $13 million milestone payment on 4 September when AstraZeneca moved the licensed compound AZD4916 into its first trial in people.

TechnologyDeveloping
Key takeaway

A Phase 1 start paid C4X $13 million without a round, a sale or a listing.

C4X Discovery, the Leeds drug-discovery company, earned a $13 million milestone payment on 4 September when AstraZeneca moved a licensed compound, AZD4916, into a Phase 1 trial, the first test of a drug in people⁠1. The licence runs to $400 million in total milestones, plus tiered mid-single-digit royalties on any eventual sales.

Milestone structures pay on events rather than outcomes. A Phase 1 start triggers cash whether or not the compound reaches a market, which turns a research company's balance sheet into something closer to a schedule than a bet. C4X did not have to sell itself, list anywhere or raise a round to collect this one.

That matters more than usual this year. British spinout deal counts fell 33%, and the listing route for a company of ambition now runs through New York rather than London. Licensing income arrives regardless of either, which is why the shape of a deal signed years ago can be worth more to a small research company than the funding environment it happens to be sitting in.

Deep Analysis

In plain English

C4X Discovery is a British drug-discovery company that licenses compounds it finds to larger pharmaceutical companies rather than developing and selling medicines itself. AstraZeneca has now started testing one of C4X's compounds, AZD4916, in its first human trial. That progress triggered a $13m payment to C4X under their licensing deal, which could be worth up to $400m in total plus a small percentage of future sales, if the drug keeps clearing trials.

First Reported In

Update #15 · Nscale takes $103.4bn of contracts to NYSE

C4X Discovery· 21 Sept 2026
Read original →
Causes and effects
This Event
C4X banks $13m as AstraZeneca doses
Licensing pays a British research company in instalments on development events, rather than only at an exit it may never reach.
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.